Facebook
Instagram
Pinterest
Reddit
Tumblr
X
Youtube
Home
About
News
Events
Shop
Directory
Contact Us
Search
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Password recovery
Recover your password
your email
A password will be e-mailed to you.
PsyNews.com
Home
About
News
Events
Shop
Directory
Contact Us
Home
Featured
Page 242
Featured
Latest
Latest
Featured posts
Most popular
7 days popular
By review score
Random
Pα+ Psychedelic Bulletin #225: Q1 Lobbying Update; Individual vs. Group MDMA Therapy Study Launches; Australia Loosens Psychedelics Access Regulations; VA Launches “New” MDMA Trial
Three Brain Injuries, One Iboga Protocol, and What It Tells Us
The War on Drugs Was Never About Drugs. Psychedelic Healing Must Reckon With That.
A Dispatch from APA’s Annual Meeting: Psychedelics Return at an Awkward Moment for American Psychiatry
Momentum Amidst Tumult: The FDA Reshuffle, Approval Timelines, and the Compass-Usona Race
Mindset Pharma Announces Preclinical Results Demonstrating Extended Duration of Action in...
MYND Life Sciences Announces $3 Million Convertible Debenture Unit Offering
MINDCURE Reaches Milestone, Releasing First of its Kind Mental Health Digital...
Clinical Director of Imperial College’s Center for Psychedelic Research Joins Entheon...
Silo Pharma Advances Psychedelic Patent Portfolio
PharmaDrug Announces Clinical Research Collaboration with The Johns Hopkins University to...
Microdosing LSD Makes Me a Better Mom
Awakn Life Sciences Initiates the First Ketamine Treatment Study for Gambling...
Tryp Therapeutics Completes Psychotherapy Training for Phase 2a Study at the...
Same But Different: Antidepressant Mechanisms of Psilocybin and Ketamine
Load more